膀胱癌多药耐药基因与p53基因表达的临床意义

Clinical significance of MDR1 and p53 gene expression in bladder transitional cell carcinoma

目的 探讨膀胱癌中多药耐药基因 (MDR1)与 p5 3基因表达的临床意义。 方法 采用免疫组化 (SABC)法对 35例膀胱移行细胞癌中MDR1表达产物P GP与p5 3基因产物 p5 3蛋白进行了检测。结果 35例膀胱移行细胞癌中P GP、p5 3阳性率分别为 40 %和 48 6 % ,随膀胱癌的病理分级和临床分期而增高。T2 ～T4 期同Tis～T1期相比 ,MDR1及p5 3的表达均有显著性差异。MDR1与p5 3的表达无相关性。同时表达MDR1及 p5 3的患者预后较差。 结论 膀胱癌中MDR1与p5 3的表达无相关性。临床检测MDR1及p5 3可对膀胱癌患者提供更多的预后信息。

Objective To study the clinical significance of the expression of multidrug resistance gene(MDR1)and p53 gene in bladder transitional cell carcinoma(BTCC). Methods P GP and p53 proteins were detected by immunohistochemical(SABC)methods in 35 BTCC specimens.Results The positive staining of P GP and p53 were 40% and 48 6% of all the specimens.The expression of MDR1 and p53 had a statistical significant difference between stages T 2～T 4 and Tis～T 1 BTCC.No correlation between MDR1 and p53 gene expression in BTCC was found.The coexpression of MDR1 and p53 had a poor prognosis.Conclusion It is shown that the coexpression of MDR1 and p53 may contribute to the prognostic value of BTCC.